🇺🇸 FDA
Patent

US 11202776

Treatment of gastroparesis with triazaspiro[4.5]decanone

granted A61KA61K31/435A61K31/438

Quick answer

US patent 11202776 (Treatment of gastroparesis with triazaspiro[4.5]decanone) held by Takeda Pharmaceutical Company Limited expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/435, A61K31/438, A61K31/454, A61P